Pharmacological interventions for people with borderline personality disorder
Open accessThe DOI matches its Crossref record; 70 of the 70 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Among people with a diagnosis of borderline personality disorder (BPD) who are engaged in clinical care, prescription rates of psychotropic medications are high, despite the fact that medication use is off-label as a treatment for BPD. Nevertheless, people with BPD often receive several psychotropic drugs at a time for sustained periods. OBJECTIVES: To assess the effects of pharmacological treatment for people with BPD. SEARCH METHODS: For this update, we searched CENTRAL, MEDLINE, Embase, 14 other databases and four trials registers up to February 2022. We contacted researchers working in the field to ask for additional data from published and unpublished trials, and handsearched relevant journals. We did not restrict the search by year of publication, language or type of publication. SELECTION CRITERIA: Randomised controlled trials comparing pharmacological treatment to placebo, other pharmacologic treatments or a combination of pharmacologic treatments in people of all ages with a formal diagnosis of BPD. The primary outcomes were BPD symptom severity, self-harm, suicide-related outcomes, and psychosocial functioning. Secondary outcomes were individual BPD symptoms, depression, attrition and adverse events. DATA COLLECTION AND ANALYSIS: At least two review authors independently selected trials, extracted data, assessed risk of bias using Cochrane's risk of bias tool and assessed the certainty of the evidence using the GRADE approach. We performed data analysis using Review Manager 5 and quantified the statistical reliability of the data using Trial Sequential Analysis. MAIN RESULTS: We included 46 randomised controlled trials (2769 participants) in this review, 45 of which were eligible for quantitative analysis and comprised 2752 participants with BPD in total. This is 18 more trials than the 2010 review on this topic. Participants were predominantly female except for one trial that included men only. The mean age ranged from 16.2 to 39.7 years across the included trials. Twenty-nine different types of medications compared to placebo or other medications were included in the analyses. Seventeen trials were funded or partially funded by the pharmaceutical industry, 10 were funded by universities or research foundations, eight received no funding, and 11 had unclear funding. For all reported effect sizes, negative effect estimates indicate beneficial effects by active medication. Compared with placebo, no difference in effects were observed on any of the primary outcomes at the end of treatment for any medication. Compared with placebo, medication may have little to no effect on BPD symptom severity, although the evidence is of very low certainty (antipsychotics: SMD -0.18, 95% confidence interval (CI) -0.45 to 0.08; 8 trials, 951 participants; antidepressants: SMD -0.27, 95% CI -0.65 to 1.18; 2 trials, 87 participants; mood stabilisers: SMD -0.07, 95% CI -0.43 to 0.57; 4 trials, 265 participants). The evidence is very uncertain about the effect of medication compared with placebo on self-harm, indicating little to no effect (antipsychotics: RR 0.66, 95% CI 0.15 to 2.84; 2 trials, 76 participants; antidepressants: MD 0.45 points on the Overt Aggression Scale-Modified-Self-Injury item (0-5 points), 95% CI -10.55 to 11.45; 1 trial, 20 participants; mood stabilisers: RR 1.08, 95% CI 0.79 to 1.48; 1 trial, 276 participants). The evidence is also very uncertain about the effect of medication compared with placebo on suicide-related outcomes, with little to no effect (antipsychotics: SMD 0.05, 95 % CI -0.18 to 0.29; 7 trials, 854 participants; antidepressants: SMD -0.26, 95% CI -1.62 to 1.09; 2 trials, 45 participants; mood stabilisers: SMD -0.36, 95% CI -1.96 to 1.25; 2 trials, 44 participants). Very low-certainty evidence shows little to no difference between medication and placebo on psychosocial functioning (antipsychotics: SMD -0.16, 95% CI -0.33 to 0.00; 7 trials, 904 participants; antidepressants: SMD -0.25, 95% CI -0.57 to 0.06; 4 trials, 161 participants; mood stabilisers: SMD -0.01, 95% CI -0.28 to 0.26; 2 trials, 214 participants). Low-certainty evidence suggests that antipsychotics may slightly reduce interpersonal problems (SMD -0.21, 95% CI -0.34 to -0.08; 8 trials, 907 participants), and that mood stabilisers may result in a reduction in this outcome (SMD -0.58, 95% CI -1.14 to -0.02; 4 trials, 300 participants). Antidepressants may have little to no effect on interpersonal problems, but the corresponding evidence is very uncertain (SMD -0.07, 95% CI -0.69 to 0.55; 2 trials, 119 participants). The evidence is very uncertain about dropout rates compared with placebo by antipsychotics (RR 1.11, 95% CI 0.89 to 1.38; 13 trials, 1216 participants). Low-certainty evidence suggests there may be no difference in dropout rates between antidepressants (RR 1.07, 95% CI 0.65 to 1.76; 6 trials, 289 participants) and mood stabilisers (RR 0.89, 95% CI 0.69 to 1.15; 9 trials, 530 participants), compa
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Cochrane Handbook for Systematic Reviews of Interventions
(2019) · doi:10.1002/9781119536604 · Cited by 14,828
GRADE guidelines: 1. Introduction—GRADE evidence profiles and summary of findings tables
Guyatt, G., Oxman, A. D., Akl, E. A., Kunz, R., Vist, G., Brozek, J., Norris, S., Falck-Ytter, Y., Glasziou, P., & deBeer, H. (2011) · Journal of Clinical Epidemiology · doi:10.1016/j.jclinepi.2010.04.026 · Cited by 10,681
Shea, B. J., Reeves, B. C., Wells, G., Thuku, M., Hamel, C., Moran, J., Moher, D., Tugwell, P., Welch, V., Kristjansson, E., et al. (2017) · BMJ · doi:10.1136/bmj.j4008 · Cited by 10,636
GRADE guidelines: 3. Rating the quality of evidence
Balshem, H., Helfand, M., Schünemann, H. J., Oxman, A. D., Kunz, R., Brozek, J., Vist, G. E., Falck-Ytter, Y., Meerpohl, J., & Norris, S. (2011) · Journal of Clinical Epidemiology · doi:10.1016/j.jclinepi.2010.07.015 · Cited by 8,285
The Global Assessment Scale: A Procedure for Measuring Overall Severity of Psychiatric Disturbance
Endicott, J. (1976) · Archives of General Psychiatry · doi:10.1001/archpsyc.1976.01770060086012 · Cited by 4,982
Development, reliability, and validity of a dissociation scale
BERNSTEIN, E. M., & PUTNAM, F. W. (1986) · The Journal of Nervous and Mental Disease · doi:10.1097/00005053-198612000-00004 · Cited by 3,793
Moher, D., Pham, B., Jones, A., Cook, D. J., Jadad, A. R., Moher, M., Tugwell, P., & Klassen, T. P. (1998) · The Lancet · doi:10.1016/s0140-6736(98)01085-x · Cited by 3,560
Assessment of suicidal intention: The Scale for Suicide Ideation.
Beck, A. T., Kovacs, M., & Weissman, A. (1979) · Journal of Consulting and Clinical Psychology · doi:10.1037//0022-006x.47.2.343 · Cited by 3,419
GRADE guidelines: 4. Rating the quality of evidence—study limitations (risk of bias)
Guyatt, G. H., Oxman, A. D., Vist, G., Kunz, R., Brozek, J., Alonso-Coello, P., Montori, V., Akl, E. A., Djulbegovic, B., & Falck-Ytter, Y. (2011) · Journal of Clinical Epidemiology · doi:10.1016/j.jclinepi.2010.07.017 · Cited by 2,798
GRADE guidelines 6. Rating the quality of evidence—imprecision
Guyatt, G. H., Oxman, A. D., Kunz, R., Brozek, J., Alonso-Coello, P., Rind, D., Devereaux, P. J., Montori, V. M., Freyschuss, B., Vist, G., et al. (2011) · Journal of Clinical Epidemiology · doi:10.1016/j.jclinepi.2011.01.012 · Cited by 2,693
Wood, L., Egger, M., Gluud, L. L., Schulz, K. F., Jüni, P., Altman, D. G., Gluud, C., Martin, R. M., Wood, A. J. G., & Sterne, J. A. C. (2008) · BMJ · doi:10.1136/bmj.39465.451748.ad · Cited by 2,538
GRADE guidelines: 7. Rating the quality of evidence—inconsistency
Guyatt, G. H., Oxman, A. D., Kunz, R., Woodcock, J., Brozek, J., Helfand, M., Alonso-Coello, P., Glasziou, P., Jaeschke, R., Akl, E. A., et al. (2011) · Journal of Clinical Epidemiology · doi:10.1016/j.jclinepi.2011.03.017 · Cited by 2,320
Meta-analyses involving cross-over trials: methodological issues
Elbourne, D. R., Altman, D. G., Higgins, J. P., Curtin, F., Worthington, H. V., & Vail, A. (2002) · International Journal of Epidemiology · doi:10.1093/ije/31.1.140 · Cited by 2,305
Osman, A., Bagge, C. L., Gutierrez, P. M., Konick, L. C., Kopper, B. A., & Barrios, F. X. (2001) · Assessment · doi:10.1177/107319110100800409 · Cited by 2,276
Inventory of interpersonal problems: Psychometric properties and clinical applications.
Horowitz, L. M., Rosenberg, S. E., Baer, B. A., Ureño, G., & Villaseñor, V. S. (1988) · Journal of Consulting and Clinical Psychology · doi:10.1037/0022-006x.56.6.885 · Cited by 2,026
GRADE guidelines: 2. Framing the question and deciding on important outcomes
Guyatt, G. H., Oxman, A. D., Kunz, R., Atkins, D., Brozek, J., Vist, G., Alderson, P., Glasziou, P., Falck-Ytter, Y., & Schünemann, H. J. (2011) · Journal of Clinical Epidemiology · doi:10.1016/j.jclinepi.2010.09.012 · Cited by 1,911
Trial sequential analysis may establish when firm evidence is reached in cumulative meta-analysis
Wetterslev, J., Thorlund, K., Brok, J., & Gluud, C. (2008) · Journal of Clinical Epidemiology · doi:10.1016/j.jclinepi.2007.03.013 · Cited by 1,881
GRADE guidelines: 8. Rating the quality of evidence—indirectness
Guyatt, G. H., Oxman, A. D., Kunz, R., Woodcock, J., Brozek, J., Helfand, M., Alonso-Coello, P., Falck-Ytter, Y., Jaeschke, R., Vist, G., et al. (2011) · Journal of Clinical Epidemiology · doi:10.1016/j.jclinepi.2011.04.014 · Cited by 1,843
GRADE guidelines: 5. Rating the quality of evidence—publication bias
Guyatt, G. H., Oxman, A. D., Montori, V., Vist, G., Kunz, R., Brozek, J., Alonso-Coello, P., Djulbegovic, B., Atkins, D., Falck-Ytter, Y., et al. (2011) · Journal of Clinical Epidemiology · doi:10.1016/j.jclinepi.2011.01.011 · Cited by 1,819
Industry sponsorship and research outcome
Lundh, A., Lexchin, J., Mintzes, B., Schroll, J. B., & Bero, L. (2017) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.mr000033.pub3 · Cited by 1,697
Grant, B. F., Chou, S. P., Goldstein, R. B., Huang, B., Stinson, F. S., Saha, T. D., Smith, S. M., Dawson, D. S., Pulay, A. J., Pickering, R. P., et al. (2008) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v69n0404 · Cited by 1,618
Borderline personality disorder
Lieb, K., Zanarini, M. C., Schmahl, C., Linehan, M. M., & Bohus, M. (2004) · The Lancet · doi:10.1016/s0140-6736(04)16770-6 · Cited by 1,369
Self-citationDSM-IV Personality Disorders in the National Comorbidity Survey Replication
Lenzenweger, M. F., Lane, M. C., Loranger, A. W., & Kessler, R. C. (2007) · Biological Psychiatry · doi:10.1016/j.biopsych.2006.09.019 · Cited by 1,352
GRADE guidelines: 9. Rating up the quality of evidence
Guyatt, G. H., Oxman, A. D., Sultan, S., Glasziou, P., Akl, E. A., Alonso-Coello, P., Atkins, D., Kunz, R., Brozek, J., Montori, V., et al. (2011) · Journal of Clinical Epidemiology · doi:10.1016/j.jclinepi.2011.06.004 · Cited by 1,336
Measurement of Deliberate Self-Harm: Preliminary Data on the Deliberate Self-Harm Inventory
Gratz, K. L. (2001) · Journal of Psychopathology and Behavioral Assessment · doi:10.1023/a:1012779403943 · Cited by 1,166
Fonagy, P., & Luyten, P. (2009) · Development and Psychopathology · doi:10.1017/s0954579409990198 · Cited by 1,146
Savović, J., Jones, H. E., Altman, D. G., Harris, R. J., Jüni, P., Pildal, J., Als-Nielsen, B., Balk, E. M., Gluud, C., Gluud, L. L., et al. (2012) · Annals of Internal Medicine · doi:10.7326/0003-4819-157-6-201209180-00537 · Cited by 1,049
Prevalence and correlates of personality disorder in Great Britain
Coid, J., Yang, M., Tyrer, P., Roberts, A., & Ullrich, S. (2006) · British Journal of Psychiatry · doi:10.1192/bjp.188.5.423 · Cited by 901
Amminger, G. P., Schäfer, M. R., Papageorgiou, K., Klier, C. M., Cotton, S. M., Harrigan, S. M., Mackinnon, A., McGorry, P. D., & Berger, G. E. (2010) · Archives of General Psychiatry · doi:10.1001/archgenpsychiatry.2009.192 · Cited by 896
Psychological therapies for people with borderline personality disorder.
Stoffers-Winterling, J. M., Völlm, B. A., Rücker, G., Timmer, A., Huband, N., & Lieb, K. (2012) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd005652.pub2 · Cited by 895
Self-citationGRADE guidelines: 12. Preparing Summary of Findings tables—binary outcomes
Guyatt, G. H., Oxman, A. D., Santesso, N., Helfand, M., Vist, G., Kunz, R., Brozek, J., Norris, S., Meerpohl, J., Djulbegovic, B., et al. (2013) · Journal of Clinical Epidemiology · doi:10.1016/j.jclinepi.2012.01.012 · Cited by 836
Treatment utilization by patients with personality disorders
Bender, D. S., Dolan, R. T., Skodol, A. E., Sanislow, C. A., Dyck, I. R., McGlashan, T. H., Shea, M. T., Zanarini, M. C., Oldham, J. M., & Gunderson, J. G. (2001) · American Journal of Psychiatry · doi:10.1176/appi.ajp.158.2.295 · Cited by 779
GRADE guidelines: 13. Preparing Summary of Findings tables and evidence profiles—continuous outcomes
Guyatt, G. H., Thorlund, K., Oxman, A. D., Walter, S. D., Patrick, D., Furukawa, T. A., Johnston, B. C., Karanicolas, P., Akl, E. A., Vist, G., et al. (2013) · Journal of Clinical Epidemiology · doi:10.1016/j.jclinepi.2012.08.001 · Cited by 772
Gunderson, J. G. (2011) · Archives of General Psychiatry · doi:10.1001/archgenpsychiatry.2011.37 · Cited by 770
Guyatt, G., Oxman, A. D., Sultan, S., Brozek, J., Glasziou, P., Alonso-Coello, P., Atkins, D., Kunz, R., Montori, V., Jaeschke, R., et al. (2013) · Journal of Clinical Epidemiology · doi:10.1016/j.jclinepi.2012.01.006 · Cited by 762
Mentalization-based treatment for self-harm in adolescents: a randomized controlled trial
Rossouw, T. I., & Fonagy, P. (2012) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1016/j.jaac.2012.09.018 · Cited by 746
Issues in the meta-analysis of cluster randomized trials
Donner, A., & Klar, N. (2002) · Statistics in Medicine · doi:10.1002/sim.1301 · Cited by 734
Skodol, A. E., Gunderson, J. G., McGlashan, T. H., Dyck, I. R., Stout, R. L., Bender, D. S., Grilo, C. M., Shea, M. T., Zanarini, M. C., Morey, L. C., et al. (2002) · American Journal of Psychiatry · doi:10.1176/appi.ajp.159.2.276 · Cited by 708
Jakobsen, J. C., Wetterslev, J., Winkel, P., Lange, T., & Gluud, C. (2014) · BMC Medical Research Methodology · doi:10.1186/1471-2288-14-120 · Cited by 704
Savović, J., Jones, H., Altman, D., Harris, R., Jűni, P., Pildal, J., Als-Nielsen, B., Balk, E., Gluud, C., Gluud, L., et al. (2012) · Health Technology Assessment · doi:10.3310/hta16350 · Cited by 668
Classification, assessment, prevalence, and effect of personality disorder
Tyrer, P., Reed, G. M., & Crawford, M. J. (2015) · The Lancet · doi:10.1016/s0140-6736(14)61995-4 · Cited by 656
Cristea, I. A., Gentili, C., Cotet, C. D., Palomba, D., Barbui, C., & Cuijpers, P. (2017) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2016.4287 · Cited by 655
The truly remarkable universality of half a standard deviation: confirmation through another look
Norman, G. R., Sloan, J. A., & Wyrwich, K. W. (2004) · Expert Review of Pharmacoeconomics & Outcomes Research · doi:10.1586/14737167.4.5.581 · Cited by 490
Zanarini, M. C., Frankenburg, F. R., Reich, D. B., & Fitzmaurice, G. (2012) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2011.11101550 · Cited by 484
Tomko, R. L., Trull, T. J., Wood, P. K., & Sher, K. J. (2014) · Journal of Personality Disorders · doi:10.1521/pedi_2012_26_093 · Cited by 483
Psychological therapies for people with borderline personality disorder
Storebø, O. J., Stoffers-Winterling, J. M., Völlm, B. A., Kongerslev, M. T., Mattivi, J. T., Jørgensen, M. S., Faltinsen, E., Todorovac, A., Sales, C. P., Callesen, H. E., et al. (2020) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd012955.pub2 · Cited by 450
Self-citationWhen and how to update systematic reviews: consensus and checklist
Garner, P., Hopewell, S., Chandler, J., MacLehose, H., Schünemann, H. J., Akl, E. A., Beyene, J., Chang, S., Churchill, R., Dearness, K., et al. (2016) · BMJ · doi:10.1136/bmj.i3507 · Cited by 426
The Economic Burden of Personality Disorders in Mental Health Care
Soeteman, D. I., Hakkaart-van Roijen, L., Verheul, R., & Busschbach, J. J. V. (2008) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v69n0212 · Cited by 417
Mustafa, R. A., Santesso, N., Brozek, J., Akl, E. A., Walter, S. D., Norman, G., Kulasegaram, M., Christensen, R., Guyatt, G. H., Falck-Ytter, Y., et al. (2013) · Journal of Clinical Epidemiology · doi:10.1016/j.jclinepi.2013.02.004 · Cited by 370
Zanarini, M. C., Frankenburg, F. R., Hennen, J., Reich, D. B., & Silk, K. R. (2005) · Journal of Personality Disorders · doi:10.1521/pedi.2005.19.5.505 · Cited by 322
Reliability and Validity of the Borderline Personality Disorder Severity Index
Arntz, A., van den Hoorn, M., Cornelis, J., Verheul, R., van den Bosch, W. M. C., & de Bie, A. J. H. T. (2003) · Journal of Personality Disorders · doi:10.1521/pedi.17.1.45.24053 · Cited by 305
Zanarini, M. C., Frankenburg, F. R., Hennen, J., & Silk, K. R. (2004) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v65n0105 · Cited by 285
Chanen, A. M., & McCutcheon, L. (2013) · British Journal of Psychiatry · doi:10.1192/bjp.bp.112.119180 · Cited by 262
Soler, J., Pascual, J. C., Campins, J., Barrachina, J., Puigdemont, D., Alvarez, E., & Pérez, V. (2005) · American Journal of Psychiatry · doi:10.1176/appi.ajp.162.6.1221 · Cited by 224
Frankenburg, F. R., & Zanarini, M. C. (2002) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v63n0511 · Cited by 221
The Burden of Disease in Personality Disorders: Diagnosis-Specific Quality of Life
Soeteman, D. I., Verheul, R., & Busschbach, J. J. V. (2008) · Journal of Personality Disorders · doi:10.1521/pedi.2008.22.3.259 · Cited by 218
Zanarini, M. C., Frankenburg, F. R., Reich, D. B., & Fitzmaurice, G. (2010) · Acta Psychiatrica Scandinavica · doi:10.1111/j.1600-0447.2010.01543.x · Cited by 210
The Pain of Being Borderline: Dysphoric States Specific to Borderline Personality Disorder
Zanarini, M. C., Frankenburg, F. R., DeLuca, C. J., Hennen, J., Khera, G. S., & Gunderson, J. G. (1998) · Harvard Review of Psychiatry · doi:10.3109/10673229809000330 · Cited by 197
Industry sponsorship and research outcome: systematic review with meta-analysis
Lundh, A., Lexchin, J., Mintzes, B., Schroll, J. B., & Bero, L. (2018) · Intensive Care Medicine · doi:10.1007/s00134-018-5293-7 · Cited by 162
Simpson, E. B., Yen, S., Costello, E., Rosen, K., Begin, A., Pistorello, J., & Pearlstein, T. (2004) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v65n0314 · Cited by 156
European guidelines for personality disorders: past, present and future
Simonsen, S., Bateman, A., Bohus, M., Dalewijk, H. J., Doering, S., Kaera, A., Moran, P., Renneberg, B., Ribaudi, J. S., Taubner, S., et al. (2019) · Borderline Personality Disorder and Emotion Dysregulation · doi:10.1186/s40479-019-0106-3 · Cited by 147
Ansell, E. B., Sanislow, C. A., McGlashan, T. H., & Grilo, C. M. (2007) · Comprehensive Psychiatry · doi:10.1016/j.comppsych.2007.02.001 · Cited by 143
Brief Reports: Prospective Assessment of Treatment Use by Patients With Personality Disorders
Bender, D. S., Skodol, A. E., Pagano, M. E., Dyck, I. R., Grilo, C. M., Shea, M. T., Sanislow, C. A., Zanarini, M. C., Yen, S., McGlashan, T. H., et al. (2006) · Psychiatric Services · doi:10.1176/appi.ps.57.2.254 · Cited by 143
Hörz, S., Zanarini, M. C., Frankenburg, F. R., Reich, D. B., & Fitzmaurice, G. (2010) · Psychiatric Services · doi:10.1176/ps.2010.61.6.612 · Cited by 118
Bellino, S., Zizza, M., Rinaldi, C., & Bogetto, F. (2006) · The Canadian Journal of Psychiatry · doi:10.1177/070674370605100707 · Cited by 81
Evaluation of naltrexone for dissociative symptoms in borderline personality disorder
Schmahl, C., Kleindienst, N., Limberger, M., Ludäscher, P., Mauchnik, J., Deibler, P., Brünen, S., Hiemke, C., Lieb, K., Herpertz, S., et al. (2012) · International Clinical Psychopharmacology · doi:10.1097/yic.0b013e32834d0e50 · Cited by 63
Self-citationWhy the Cochrane Risk of Bias Tool Should not Include Funding Source as a Standard Item
Sterne, J. A. (2013) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.ed000076 · Cited by 60
Borderline personality and psychotropic medication prescription in an outpatient psychiatry clinic
Sansone, R. A., Rytwinski, D., & Gaither, G. A. (2003) · Comprehensive Psychiatry · doi:10.1016/s0010-440x(03)00147-0 · Cited by 46
Hastrup, L. H., Kongerslev, M. T., & Simonsen, E. (2019) · Journal of Personality Disorders · doi:10.1521/pedi_2018_32_344 · Cited by 44
Self-citationMedication utilization patterns and methods of suicidality in borderline personality disorder
Makela, E. H., Moeller, K. E., Fullen, J. E., & Gunel, E. (2006) · Annals of Pharmacotherapy · doi:10.1345/aph.1e479 · Cited by 18
Cited by
Leichsenring, F., Fonagy, P., Heim, N., Kernberg, O. F., Leweke, F., Luyten, P., Salzer, S., Spitzer, C., & Steinert, C. (2024) · World Psychiatry · doi:10.1002/wps.21156 · Cited by 294
Early intervention for personality disorder
Chanen, A. M., Sharp, C., Nicol, K., & Kaess, M. (2022) · Focus · doi:10.1176/appi.focus.20220062 · Cited by 38
Pharmacological management of personality disorders: from evidence to practice
Völlm, B., & Cerci, D. (2025) · BJPsych Advances · doi:10.1192/bja.2024.30 · Cited by 4
Positive Self-Relation Scale – development and psychometric properties
Ociskova, M., Prasko, J., & Kupka, M. (2019) · Psychology Research and Behavior Management · doi:10.2147/prbm.s212923 · Cited by 2
Metadata
- Authors
- Stoffers-Winterling, J. M., Storebø, O. J., Pereira Ribeiro, J., Kongerslev, M. T., Völlm, B. A., Mattivi, J. T., Faltinsen, E., Todorovac, A., Jørgensen, M. S., Callesen, H. E., Sales, C. P., Schaug, J. P., Simonsen, E., & Lieb, K.
- Venue
- Cochrane Database of Systematic Reviews
- Publisher
- Wiley
- Published
- 2022-11-14
- Volume
- 2022
- Issue
- 11
- Pages
- CD012956-CD012956
- ISSN
- 1361-6137 (ISSN-L)
- 1465-1858
- OpenAlex
- W4308964737
- Cited by
- 108
- References
- 70
- FWCI
- 18.66
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.